Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bcl-xl expression in multiple myeloma.

S D P W M Peeters1, S Hovenga, S Rosati

  • 1Department of Hematology, University Hospital Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.

Medical Oncology (Northwood, London, England)
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024
Same author

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.

Leukemia & lymphoma·2020
Same author

Efficacy of antithymocyte globulin as first-line treatment for aplastic anemia-a single-center experience.

Annals of hematology·2017
Same author

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Journal of internal medicine·2017
Same author

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Leukemia·2017
Same author

Measurements of top-quark pair differential cross-sections in the lepton+jets channel in <i>pp</i> collisions at [Formula: see text] using the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same journal

Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery.

Medical oncology (Northwood, London, England)·2026
Same journal

Expedited regulatory approval pathways for novel oncology drugs.

Medical oncology (Northwood, London, England)·2026
Same journal

Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.

Medical oncology (Northwood, London, England)·2026
Same journal

DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.

Medical oncology (Northwood, London, England)·2026
Same journal

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Medical oncology (Northwood, London, England)·2026
Same journal

Unraveling the link between genomic instability and tumor immune evasion in oral squamous cell carcinoma: Role of CBMN assay and emerging perspectives.

Medical oncology (Northwood, London, England)·2026
See all related articles

Bcl-xl, a target of signal transducer and activator of transcription-3 (Stat3), was studied in multiple myeloma (MM). Elevated Bcl-xl expression was found in some MM patients but did not correlate with clinical outcomes or common biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled proliferation of plasma cells.
  • Interleukin-6 (IL-6) signaling pathway, involving signal transducer and activator of transcription-3 (Stat3), plays a crucial role in MM pathogenesis.
  • Bcl-xl is a downstream target of the IL-6/Stat3 pathway and is implicated in cell survival and apoptosis.

Purpose of the Study:

  • To investigate the immunohistochemical expression of Bcl-xl in multiple myeloma patients.
  • To analyze the correlation between Bcl-xl expression and clinical parameters such as C-reactive protein (CRP), beta-2-microglobulin (beta2m), and microvessel density (MVD).
  • To evaluate the association of Bcl-xl expression with clinical outcomes, including overall survival and event-free survival.

Related Experiment Videos

Main Methods:

  • Immunohistochemistry was used to assess Bcl-xl expression in 40 newly diagnosed MM cases and 11 relapsed MM cases.
  • Correlation analysis was performed between Bcl-xl expression levels and serum levels of CRP and beta2m.
  • Microvessel density (MVD) was quantified, and its correlation with Bcl-xl expression and clinical outcome was assessed.

Main Results:

  • Bcl-xl expression was found to be elevated in a subgroup (30%) of MM patients before treatment, with no change observed at relapse.
  • No significant correlation was found between Bcl-xl expression and CRP or beta2m levels.
  • While MVD was significantly increased in MM patients compared to normal controls, no significant correlation was observed between Bcl-xl expression and MVD. Furthermore, Bcl-xl expression levels did not correlate with overall or event-free survival.

Conclusions:

  • Bcl-xl is elevated in a subset of multiple myeloma patients.
  • The elevated Bcl-xl expression in MM does not appear to correlate with established biomarkers like CRP, beta2m, or MVD.
  • Current findings suggest that Bcl-xl expression, as assessed by immunohistochemistry, does not predict clinical outcome in multiple myeloma patients.